Timing is everything: new lung cancer trial aims to boost treatment by scheduling infusions just right
NCT ID NCT07190027
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 28 times
Summary
This study tests whether giving immunotherapy and chemotherapy at different times can help people with advanced non-small cell lung cancer (NSCLC) that lacks certain gene mutations. About 246 adults will be split into three groups: same-day treatment, chemotherapy two days before immunotherapy, or a personalized schedule based on daily immune system monitoring. The goal is to see if personalized timing improves tumor shrinkage and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.